Given the advantages over its rivals, Regeneron is hopeful its bispecific antibody will become the new standard of care for ...

Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is one of the most undervalued large cap stocks to buy according to analysts. On ...

The FDA has granted accelerated approval to linvoseltamab-gcpt (Lynozyfic) for the treatment of adult patients with ...

This approval comes almost a year after the drug received a complete response letter due to third-party manufacturing issues.

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval for Lynozyfic™ (linvoseltamab-gcpt) to treat adult ...

The FDA granted accelerated approval of linvoseltamab-gcpt for certain patients with multiple myeloma.Specifically, the ...

The FDA approved Lynozyfic (linvoseltamab-gcpt) to treat adults with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

A B-cell maturation antigen (BCMA)-directed bispecific antibody, linvoseltamab is indicated for adult patients who have ...

Accelerated approval was based on results from the Phase I/II LINKER-MM1 trial, which showed a 70% objective response rate in ...

NEW YORK - The U.S. Food and Drug Administration has granted accelerated approval to Regeneron Pharmaceuticals’ (NASDAQ:REGN) Lynozyfic (linvoseltamab-gcpt) for adult patients with relapsed or ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Regeneron Pharmaceuticals’ Lynozyfic (linvoseltamab-gcpt) has been granted accelerated approval by the US Food and Drug ...